Key facts
- InterVene’s last known valuation is $24.9M.
- It has raised $37.9M across 4 recorded rounds; the latest was Seed Round ($1.5M) in Feb 2023.
- Notable investors include Correlation Ventures, Stanford University Venture Fund, North Texas Angel Network, American Century Investments, Boston Scientific Ventures — 11 tracked in total.
- InterVene has filed 4 Form Ds with the SEC since 2015, most recently Mar 2023 ($1.5M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for InterVene
Funding rounds
4 roundsAbout InterVene
Developer of medical devices designed to correct deep vein valve failure. The company's devices consist of a range of non-implantable, catheter-based therapies to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their hearts, enabling doctors to form new vein valves out of their own vein wall tissue.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2011
- Employees
- 17
- Website
- intervene-med.com/
- Ownership
- Privately Held (backing)
InterVene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InterVene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InterVene in its N-PORT filings yet. We sweep new filings monthly.